Intensive diabetes therapy and ocular surgery in type 1 diabetes

DCCT/EDIC Research Group, Lloyd Paul Aiello, Wanjie Sun, Arup Das, Sapna Gangaputra, Szilard Kiss, Ronald Klein, Patricia A Cleary, John M Lachin, David M Nathan

Abstract

Background: The Diabetes Control and Complications Trial (DCCT) showed a beneficial effect of 6.5 years of intensive glycemic control on retinopathy in patients with type 1 diabetes.

Methods: Between 1983 and 1989, a total of 1441 patients with type 1 diabetes in the DCCT were randomly assigned to receive either intensive diabetes therapy or conventional therapy aimed at preventing hyperglycemic symptoms. They were treated and followed until 1993. Subsequently, 1375 of these patients were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. The self-reported history of ocular surgical procedures was obtained annually. We evaluated the effect of intensive therapy as compared with conventional therapy on the incidence and cost of ocular surgery during these two studies.

Results: Over a median follow-up of 23 years, 130 ocular operations were performed in 63 of 711 patients assigned to intensive therapy (8.9%) and 189 ocular operations in 98 of 730 patients assigned to conventional therapy (13.4%) (P<0.001). After adjustment for DCCT baseline factors, intensive therapy was associated with a reduction in the risk of any diabetes-related ocular surgery by 48% (95% confidence interval [CI], 29 to 63; P<0.001) and a reduction in the risk of all such ocular procedures by 37% (95% CI, 12 to 55; P=0.01). Forty-two patients who received intensive therapy and 61 who received conventional therapy underwent cataract extraction (adjusted risk reduction with intensive therapy, 48%; 95% CI, 23 to 65; P=0.002); 29 patients who received intensive therapy and 50 who received conventional therapy underwent vitrectomy, retinal-detachment surgery, or both (adjusted risk reduction, 45%; 95% CI, 12 to 66; P=0.01). The costs of surgery were 32% lower in the intensive-therapy group. The beneficial effects of intensive therapy were fully attenuated after adjustment for mean glycated hemoglobin levels over the entire follow-up.

Conclusions: Intensive therapy in patients with type 1 diabetes was associated with a substantial reduction in the long-term risk of ocular surgery. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360893 and NCT00360815.).

Figures

Figure 1. Cumulative Incidence of Diabetes-Related Ocular…
Figure 1. Cumulative Incidence of Diabetes-Related Ocular Surgery, According to Treatment Group and Type of Surgery
CI denotes confidence interval.
Figure 2. Risk Reduction in the Intensive-Therapy…
Figure 2. Risk Reduction in the Intensive-Therapy Group versus the Conventional-Therapy Group, as a Function of Age at Baseline in the DCCT, According to Type of Surgery
Dashed lines indicate 95% confidence intervals.

References

    1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. .
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
    1. The DCCT/EDIC Research Group. Epidemiology of diabetes interventions and complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99–111.
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–389.
    1. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563–2569.
    1. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653.
    1. Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64:631–642.
    1. de Boer IH, Afkarian M, Rue TC, et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2014;25:2342–2350.
    1. Newman-Casey PA, Talwar N, Nan B, Musch DC, Stein JD. The relationship between components of metabolic syndrome and open-angle glaucoma. Ophthalmology. 2011;118:1318–1326.
    1. Klein BE, Klein R, Moss SE. Prevalence of cataracts in a population-based study of persons with diabetes mellitus. Ophthalmology. 1985;92:1191–1196.
    1. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels: International Diabetes Federation; 2013.
    1. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagu-lation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;1991;98(Suppl):766–785.
    1. Steffes M, Cleary P, Goldstein D, et al. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Clin Chem. 2005;51:753–758.
    1. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
    1. de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomeru-lar filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366–2376.
    1. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010;33:1090–1096.
    1. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154.
    1. Lachin JM. Biostatistical methods: the assessment of relative risks. 2nd ed. New York: Wiley; 2011.
    1. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074–1078.
    1. Busbee BG, Brown MM, Brown GC, Sharma S. Cost-utility analysis of cataract surgery in the second eye. Ophthalmology. 2003;110:2310–2317.
    1. Schmier JK, Covert DW, Lau EC, Robin AL. Trends in annual Medicare expenditures for glaucoma surgical procedures from 1997 to 2006. Arch Ophthalmol. 2009;127:900–905.
    1. SAS Institute. SAS/STAT 9.2 User’s guide. Cary, NC: SAS Institute; 2008.
    1. DCCT/EDIC Research Group. Intensive therapy and GFR in type 1 diabetes. N Engl J Med. 2011;365:2366–2376.
    1. Centers for Disease Control and Prevention. U.S. outpatient surgeries on the rise. Press release: January 28, 2009. .
    1. Centers for Medicare and Medicaid Services. Current Procedural Terminology (CPT) (Fourth Edition) 2010 .
    1. Dowler J, Hykin PG. Cataract surgery in diabetes. Curr Opin Ophthalmol. 2001;12:175–178.
    1. Haddad NM, Sun JK, Abujaber S, Schlossman DK, Silva PS. Cataract surgery and its complications in diabetic patients. Semin Ophthalmol. 2014;29:329–337.
    1. Klein BE, Klein R, Moss SE. Incidence of cataract surgery in the Wisconsin Epi-demiologic Study of Diabetic Retinopa-thy. Am J Ophthalmol. 1995;119:295–300.
    1. Olafsdottir E, Andersson DK, Stefáns-son E. The prevalence of cataract in a population with and without type 2 diabetes mellitus. Acta Ophthalmol. 2012;90:334–340.
    1. Klein BE, Klein R, Lee KE. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study. Am J Ophthalmol. 1998;126:782–790.
    1. Hashim Z, Zarina S. Advanced glycation end products in diabetic and non-diabetic human subjects suffering from cataract. Age (Dordr) 2011;33:377–384.
    1. Sensi M, Pricci F, Pugliese G, et al. Role of advanced glycation end-products (AGE) in late diabetic complications. Diabetes Res Clin Pract. 1995;28:9–17.
    1. Ramalho J, Marques C, Pereira P, Mota MC. Crystallin composition of human cataractous lens may be modulated by protein glycation. Graefes Arch Clin Exp Ophthalmol. 1996;234(Suppl 1):S232–S238.
    1. Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of Maillard reaction in the aging eye. Amino Acids. 2012;42:1205–1220.
    1. Monnier VM, Sell DR, Strauch C, et al. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. J Diabetes Complications. 2013;27:141–149.
    1. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 1999;48:870–880.
    1. Grassi MA, Sun W, Gangaputra S, et al. Validity of self-report in type 1 diabetic subjects for laser treatment of retinopathy. Ophthalmology. 2013;120:2580–256.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться